Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalja Strelkowa

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Chaos (Woodbury, N.Y.)|July 5, 2011
Transient dynamics around unstable periodic orbits in the generalized repressilator modelNatalja Strelkowa, Mauricio Barahona
Genetics|August 2, 2012
Clonal interference in the evolution of influenzaNatalja Strelkowa, Michael Lässig
Journal of the Royal Society, Interface|January 26, 2010
Switchable genetic oscillator operating in quasi-stable modeNatalja Strelkowa, Mauricio Barahona
Journal of the Royal Society, Interface|February 11, 2009
Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systemsTina Toni, David Welch, Natalja Strelkowa, et al.
Journal of Clinical Pharmacology|October 30, 2014
Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteersDavid Joseph, Peter Rose, Natalja Strelkowa, et al.
EMBO Reports|June 16, 2012
Engineering and ethical perspectives in synthetic biology. Rigorous, robust and predictable designs, public engagement and a modern ethical framework are vital to the continued success of synthetic biologyJames Anderson, Natalja Strelkowa, Guy-Bart Stan, et al.
Journal of Clinical Pharmacology|May 18, 2017
Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover StudyFenglei Huang, Kristell Marzin, Rüdiger Koenen, et al.
Cancer Chemotherapy and Pharmacology|September 10, 2015
A phase I study of volasertib combined with afatinib, in advanced solid tumorsJean-Pascal Machiels, Marc Peeters, Catherine Herremans, et al.
British Journal of Cancer|March 13, 2020
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursJohann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Chaos (Woodbury, N.Y.)|July 5, 2011
Transient dynamics around unstable periodic orbits in the generalized repressilator modelNatalja Strelkowa, Mauricio Barahona
Genetics|August 2, 2012
Clonal interference in the evolution of influenzaNatalja Strelkowa, Michael Lässig
Journal of the Royal Society, Interface|January 26, 2010
Switchable genetic oscillator operating in quasi-stable modeNatalja Strelkowa, Mauricio Barahona
Journal of the Royal Society, Interface|February 11, 2009
Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systemsTina Toni, David Welch, Natalja Strelkowa, et al.
Journal of Clinical Pharmacology|October 30, 2014
Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteersDavid Joseph, Peter Rose, Natalja Strelkowa, et al.
EMBO Reports|June 16, 2012
Engineering and ethical perspectives in synthetic biology. Rigorous, robust and predictable designs, public engagement and a modern ethical framework are vital to the continued success of synthetic biologyJames Anderson, Natalja Strelkowa, Guy-Bart Stan, et al.
Journal of Clinical Pharmacology|May 18, 2017
Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover StudyFenglei Huang, Kristell Marzin, Rüdiger Koenen, et al.
Cancer Chemotherapy and Pharmacology|September 10, 2015
A phase I study of volasertib combined with afatinib, in advanced solid tumorsJean-Pascal Machiels, Marc Peeters, Catherine Herremans, et al.
British Journal of Cancer|March 13, 2020
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursJohann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.
Pageof 1